MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma

Journal of Clinical Immunology

Volumn 32, Issue 3, 2012, Pages 514-522

  Zhu, Honglin ^a   Li, Yisha ^a   Qu, Shunlin ^c   Luo, Hui ^a   Zhou, Yaou ^a   Wang, Yanping ^a   Zhao, Hongjun ^a   You, Yunhui ^a   Xiao, Xianzhong ^b   Zuo, Xiaoxia ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

microarray; microRNA; Scleroderma; target gene

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 1 ALPHA 2; COLLAGEN TYPE 1 ALPHA 3; MESSENGER RNA; MICRORNA; MICRORNA 145; MICRORNA 146; MICRORNA 21; MICRORNA 29B; MICRORNA 31; MICRORNA 503; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COL1A1 GENE; CONTROLLED STUDY; DIFFUSE SCLERODERMA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMITED SCLERODERMA; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROSIS; SMAD3 GENE; SMAD7 GENE;

ADULT; COLLAGEN TYPE I; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; RNA, MESSENGER; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84862829123     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9647-y     Document Type: Article

References (24)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003.
2. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-5.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-67. (Pubitemid 46348510)
4. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350-8. (Pubitemid 30408720)
5. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum. 2002;46(7):1857-65. (Pubitemid 34774518)
6. Gabrielli A, Di Loreto C, Taborro R, Candela M, Sambo P, Nitti C, et al. Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol. 1993;68(3):340-9. (Pubitemid 23284094)
7. Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC. Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol. 1993;69(2):199-204. (Pubitemid 23319388)
8. Xu WD, Leroy EC, Smith EA. Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta. J Rheumatol. 1991;18(2):241-6.
9. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum. 2002;46(7):1703-13. (Pubitemid 34774500)
10. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10(2):111-22.
11. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9(3):219-30. (Pubitemid 351301826)
12. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175-205.
13. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J. 2010;277(9):2015-21.
14. Li H, Yang R, Fan X, Gu T, Zhao Z, Chang D, et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int. 2010;32(2):307-13.
15. Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62(6):1733-43.
16. Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria ofthe American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-90.
17. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010;130(3):694-705.
18. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210. (Pubitemid 351160157)
19. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet. 2009;10(8):578-85.
20. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res. 2008;103(9):919-28.
21. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896-9. (Pubitemid 351550859)
22. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to upregulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36(4):1153-62. (Pubitemid 351330933)
23. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87-98.
24. Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, et al. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci. 2011;61(1):67-9.